Nektar Therapeutics (NKTR): Price and Financial Metrics

Nektar Therapeutics (NKTR)

Today's Latest Price: $17.84 USD

0.04 (0.22%)

Updated Jan 15 9:50am

Add NKTR to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 481 in Biotech

See all "A" rated Strong Buy stocks

NKTR Stock Summary

  • Of note is the ratio of Nektar Therapeutics's sales and general administrative expense to its total operating expenses; just 9.29% of US stocks have a lower such ratio.
  • With a price/sales ratio of 19.55, Nektar Therapeutics has a higher such ratio than 89.82% of stocks in our set.
  • With a year-over-year growth in debt of -61.66%, Nektar Therapeutics's debt growth rate surpasses only 4.56% of about US stocks.
  • If you're looking for stocks that are quantitatively similar to Nektar Therapeutics, a group of peers worth examining would be NERV, AGIO, ASMB, CYCN, and PRQR.
  • Visit NKTR's SEC page to see the company's official filings. To visit the company's web site, go to

NKTR Stock Price Chart Interactive Chart >

Price chart for NKTR

NKTR Price/Volume Stats

Current price $17.84 52-week high $25.06
Prev. close $17.80 52-week low $13.63
Day low $17.75 Volume 99,191
Day high $18.10 Avg. volume 895,823
50-day MA $17.57 Dividend yield N/A
200-day MA $19.60 Market Cap 3.20B

Nektar Therapeutics (NKTR) Company Bio

Nektar Therapeutics is a biopharmaceutical company, developing drug candidates that utilize its PEGylation and polymer conjugate technology platforms in the United States. Its product pipeline includes drug candidates in therapeutic areas comprising oncology, pain, anti-infectives, and immunology.

NKTR Latest News Stream

Event/Time News Detail
Loading, please wait...

NKTR Latest Social Stream

Loading social stream, please wait...

View Full NKTR Social Stream

Latest NKTR News From Around the Web

Below are the latest news stories about Nektar Therapeutics that investors may wish to consider to help them evaluate NKTR as an investment opportunity.

Nektar Therapeutics' President and CEO, Howard Robin, to Present at the 39th Annual J.P. Morgan Virtual Healthcare Conference

Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard Robin, is scheduled to present at the upcoming 39th Annual J.P. Morgan Virtual Healthcare Conference on Monday, January 11, 2021 at 11:50 a.m. Pacific Time. The presentation and Q&A; session will be accessible via a Webcast through a link posted on the Investor Events Calendar section of the Nektar website: This webcast will be available for replay until February 10, 2021.

Yahoo | January 6, 2021

The Daily Biotech Pulse: Aerpio Reviews Strategic Options, Hologic Goes Shopping

Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 5) * Curis, Inc. (NASDAQ: CRIS) * Endo International PLC (NASDAQ: ENDP) * Fulgent Genetics Inc (NASDAQ: FLGT) * Genmab 10 Sponsored ADR Ord Shs (NASDAQ: GMAB) * \I-Mab ADR (NASDAQ: IMAB) * Jaguar Health Inc (NASDAQ: JAGX) * Johnson & Johnson (NYSE: JNJ) * LeMaitre Vascular Inc (NASDAQ: LMAT) * Oncorus Inc (NASDAQ: ONCR) * Organogenesis Holdings Inc (NASDAQ: ORGO) * Pulse Biosciences Inc (NASDAQ: PLSE) * Renalytix AI PLC (NASDAQ: RNLX) (announced a partnership with Davita Inc (NYSE: DVA) aimed at slowing disease progression and improving health outcomes in with chronic kidney disease patients) * Shockwave Medical Inc (NASDAQ: SWAV) * ...

Yahoo | January 6, 2021

Nektar Appoints Dr. Brian Kotzin as Interim Chief Medical Officer and Head of Development

Nektar Therapeutics (NASDAQ: NKTR) announced today that it has appointed Brian Kotzin, MD as Interim Chief Medical Officer, Head of Development effective immediately. Since 2017, Dr. Kotzin has served as Senior Vice President, Clinical Development and Head of Immunology at Nektar. Wei Lin will be leaving the company to pursue another opportunity.

Yahoo | January 5, 2021

Nektar to sell Adynovate, Movantik Royalties for $150M

Nektar (NKTR) has agreed to sell its royalties on future sales of Adynovate (Under Baxalta agreement) and Movantik (under AstraZeneca pact) to Healthcare Royalty, for $150M.Proceeds will be used for funding of clinical trials for Nektar early and late stage immune-oncology programs“This non-dilutive financing strengthens our financial position as we continue...

Seeking Alpha | December 22, 2020

Implied Volatility Surging for Nektar Therapeutics (NKTR) Stock Options

Investors need to pay close attention to Nektar Therapeutics (NKTR) stock based on the movements in the options market lately.

Yahoo | December 22, 2020

Read More 'NKTR' Stories Here

NKTR Price Returns

1-mo 1.02%
3-mo 4.08%
6-mo -26.80%
1-year -25.36%
3-year -74.42%
5-year 27.34%
YTD 4.94%
2020 -21.24%
2019 -34.33%
2018 -44.96%
2017 386.72%
2016 -27.18%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8589 seconds.